D Tougeron

Summary

Country: France

Publications

  1. doi request reprint Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
    David Tougeron
    Department of Gastroenterology, Poitiers University Hospital, 2 rue de la Miletrie, Poitiers Cedex, France
    Cancer Chemother Pharmacol 72:397-403. 2013
  2. pmc Regulatory T lymphocytes are associated with less aggressive histologic features in microsatellite-unstable colorectal cancers
    David Tougeron
    INSERM, U1079, Faculty of Medicine, Institute for Medical Research, Rouen University Hospital, Rouen, France
    PLoS ONE 8:e61001. 2013
  3. doi request reprint Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
    D Tougeron
    Department of Gastroenterology, Poitiers University Hospital, 2 rue de la Miletrie, 86000 Poitiers cedex, France
    Ann Oncol 24:1267-73. 2013
  4. doi request reprint [Immune response and colorectal cancer]
    David Tougeron
    CHU de Poitiers, Service d Hepato gastro enterologie, 2, rue de la Miletrie, 86000 Poitiers cedex, France
    Bull Cancer 100:283-94. 2013
  5. doi request reprint Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery?
    D Tougeron
    Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital Charles Nicolle, Northwest Canceropole, France
    J Surg Oncol 105:761-6. 2012
  6. doi request reprint Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres
    David Tougeron
    Department of Gastroenterology, Poitiers University Hospital, Cancéropôle Grand Ouest, Poitiers, France
    Dig Liver Dis 44:350-4. 2012
  7. doi request reprint Management of esophageal adenocarcinoma
    D Tougeron
    Service d Hepato Gastroenterologie, CHU de Poitiers, 2, rue de la Miletrie, 86000 Poitiers cedex, France
    J Visc Surg 148:e161-70. 2011
  8. ncbi request reprint Unusual skeletal muscle metastasis from gastric adenocarcinoma
    D Tougeron
    Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital, Northwest Canceropole, Rouen, France
    Gastroenterol Clin Biol 33:485-7. 2009
  9. doi request reprint Control of pelvic symptoms in patients with rectal cancer and synchronous metastases
    D Tougeron
    Digestive Oncology Unit, Department of Gastroenterology, Northwest Canceropole, Rouen University Hospital, 1 rue de Germont, Rouen Cedex, France
    Gastroenterol Clin Biol 33:1106-13. 2009
  10. pmc Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer
    D Tougeron
    Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital, Northwest Canceropole, Rouen Cedex, France
    Br J Cancer 99:1586-92. 2008

Collaborators

Detail Information

Publications12

  1. doi request reprint Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
    David Tougeron
    Department of Gastroenterology, Poitiers University Hospital, 2 rue de la Miletrie, Poitiers Cedex, France
    Cancer Chemother Pharmacol 72:397-403. 2013
    ..A KRAS mutation was found after anti-EGFR mAb in only one tumor. Our results suggest that acquired EGFR S492R and KRAS mutations do not constitute the main mechanism of resistance to anti-EGFR mAb in combination with chemotherapy. ..
  2. pmc Regulatory T lymphocytes are associated with less aggressive histologic features in microsatellite-unstable colorectal cancers
    David Tougeron
    INSERM, U1079, Faculty of Medicine, Institute for Medical Research, Rouen University Hospital, Rouen, France
    PLoS ONE 8:e61001. 2013
    ..We have undertaken to determine the link between TIL densities and MSI CRC histologic features...
  3. doi request reprint Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
    D Tougeron
    Department of Gastroenterology, Poitiers University Hospital, 2 rue de la Miletrie, 86000 Poitiers cedex, France
    Ann Oncol 24:1267-73. 2013
    ..Up until now, the impact of low-frequency KRAS mutations (<10%) on the response to anti-EGFR Mabs has yet to be evaluated...
  4. doi request reprint [Immune response and colorectal cancer]
    David Tougeron
    CHU de Poitiers, Service d Hepato gastro enterologie, 2, rue de la Miletrie, 86000 Poitiers cedex, France
    Bull Cancer 100:283-94. 2013
    ..These data should be considered for the treatment of CRC or the development of immunotherapy strategies...
  5. doi request reprint Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery?
    D Tougeron
    Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital Charles Nicolle, Northwest Canceropole, France
    J Surg Oncol 105:761-6. 2012
    ..Data concerning the usefulness of definitive CRT in patients with esophageal adenocarcinoma (ADC) are lacking. The aim of the study was to compare the results of definitive CRT versus surgery in patients with an ADC...
  6. doi request reprint Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres
    David Tougeron
    Department of Gastroenterology, Poitiers University Hospital, Cancéropôle Grand Ouest, Poitiers, France
    Dig Liver Dis 44:350-4. 2012
    ..The risks of chemoradiotherapy in elderly patients with rectal cancer have not yet been well-characterised...
  7. doi request reprint Management of esophageal adenocarcinoma
    D Tougeron
    Service d Hepato Gastroenterologie, CHU de Poitiers, 2, rue de la Miletrie, 86000 Poitiers cedex, France
    J Visc Surg 148:e161-70. 2011
    ..For patients with contraindications to surgery, exclusive chemoradiation therapy is recommended. Herein we reviewed and synthesized the different therapeutic strategies for esophageal adenocarcinoma...
  8. ncbi request reprint Unusual skeletal muscle metastasis from gastric adenocarcinoma
    D Tougeron
    Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital, Northwest Canceropole, Rouen, France
    Gastroenterol Clin Biol 33:485-7. 2009
    ..The patient is alive and free of recurrence in the deltoid muscle after a follow-up of 13 months. Based on this case study, the difficulty of diagnosing skeletal muscle metastases, the prognosis and treatment options are discussed...
  9. doi request reprint Control of pelvic symptoms in patients with rectal cancer and synchronous metastases
    D Tougeron
    Digestive Oncology Unit, Department of Gastroenterology, Northwest Canceropole, Rouen University Hospital, 1 rue de Germont, Rouen Cedex, France
    Gastroenterol Clin Biol 33:1106-13. 2009
    ..The optimal treatment strategy for rectal cancer (RC) with synchronous metastases remains an issue of debate. The aim of this study was to evaluate the impact of surgery and radiation on the control of pelvic symptoms in this setting...
  10. pmc Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer
    D Tougeron
    Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital, Northwest Canceropole, Rouen Cedex, France
    Br J Cancer 99:1586-92. 2008
    ..046) were identified as independent prognostic factors of overall survival. These results suggest that CRT could be considered as an effective treatment without major toxicity in elderly patients with OC...
  11. pmc TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
    A Oden-Gangloff
    INSERM U614, Faculty of Medicine, Institute for Biomedical Research, University of Rouen, Rouen, France
    Br J Cancer 100:1330-5. 2009
    ....
  12. doi request reprint Unusual iris metastasis from anal cancer: a case report
    D Tougeron
    Department of Hepatogastroenterology, Rouen University Hospital, Rouen, France
    Dig Liver Dis 41:e1-3. 2009
    ..Anal carcinoma can metastasize to the iris. Radiotherapy allows a good local control of tumour but the prognosis depends on systemic disease which is generally bad...